RBC Capital Upgrades Pharmacyclics (PCYC) to Outperform
Tweet
Share
E-mailGet Alerts PCYC Hot Sheet
Price: $261.25 --0%
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 39
Rating Summary:
5 Buy, 17 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 39
Join SI Premium – FREE
RBC Capital upgraded Pharmacyclics (NASDAQ: PCYC) from Sector Perform to Outperform, price target raised from $15 to $34.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $24.48 yesterday.
For an analyst ratings summary and ratings history on Pharmacyclics click here. For more ratings news on Pharmacyclics click here.
Shares of Pharmacyclics closed at $24.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Upgrades New Oriental Education (EDU) to Buy
- Jefferies Upgrades General Dynamics Corp. (GD) to Buy 'As Marine Bridges This OG to Growth'
- Goldman Sachs Upgrades New Oriental Education & Technology Group (9901:HK) (EDU) to Buy
Create E-mail Alert Related Categories
Analyst PT Change, UpgradesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
